Peptide compositions
AssigneeRhythm Pharmaceuticals, Inc.
InventorsShubh Sharma, Leonardus H.T. Van Der Ploeg, Bart Henderson
Life of this patent
Estimating the term…
Abstract
The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.
Claims23
An isolated polypeptide of the following structural Formula (I):
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is —H, or a C1-C6 acyl;
- R2 is —NR3R4, or —OR5 wherein R3, R4, and R5 are each independently is H or a C1-C6 alkyl;
- A1 is an amino acid residue selected from Arg, Lys, Orn, His, Nle, Phe, Val, Leu, Trp, Tyr, Ala, Ser, Thr, Gln, Asn, Asp, Glu, or TzAla;
- or
- A1 is a moiety selected from an optionally substituted C1-C12 alkyl, an optionally substituted C6-C18 aryl, an optionally substituted C5-C18 heteroaryl, an aralkyl wherein the aryl portion is an optionally substituted C6-C18 aryl, and the alkyl portion is an optionally substituted C1-C12 alkyl, or a heteroaralkyl, wherein the heteroaryl portion is an optionally substituted C5-C18 heteroaryl, and the alkyl portion is an optionally substituted C1-C12 alkyl;
- or
- A1 is absent;
- or
- A2 and A8 is each independently an amino acid residue selected from Cys, hCys, Pen, Asp, Glu, Lys, Orn, Dbu, or Dpr, wherein A2 and A8 are pairwise selected so as to be able to form covalent bond between their respective side chains;
- A3 is an amino acid residue selected from Ala, Tle, Val, Leu, Ile, Cha, Pro, Ser, Thr, Lys, Arg, His, Phe, Gln, Sar, Gly, Asn, Aib, or
- A3 is absent, or
- A3 is residue Y, wherein Y is an amino acid selected from amino acids represented by the following structural formulas
- wherein:
- R11 and R12, each independently, is H, —CH3, phenyl, or benzyl;
- R21, R22, R23, and R24, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
- R31, R32, R33, R34, R41, R42, and R43, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
- A4 is absent or is an amino acid residue selected from Atc, Ala, QAla, Aib, Sar, Ser, Thr, Pro, Hyp, Asn, Gln, an optionally substituted His, Trp, Tyr, Lys, Arg, sChp, or residue X, where the X is an amino acid selected from amino acids represented by the following structural formulas:
- wherein:
- R51 and R52, each independently, is H, —CH3, phenyl, or benzyl;
- R61, R62, R63, and R64, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
- R71, R72, R73, R74, R81, R82, and R83, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
- A5 is an optionally substituted Phe, an optionally substituted 1-Nal, or an optionally substituted 2-Nal;
- A6 is Arg;
- and
- A7 is Trp,
- wherein any amino acid residue is either in L- or in D-configuration, provided that:
- 1) A3 and A4 are not both absent;
- 2) when A4 is an amino acid, A3 is not Aib or Gly;
- and
- 3) when A4 is His and A5 is a D-Phe or 2-Nal, A3 is not a D-amino acid or L-Ala;
- 4) when A2 and A8 each is selected from Cys, hCys or Pen, then:
- (a) when A4 is absent, then A3 is not L-His;
- (b) when A3 is absent, then A4 is not L-His;
- and
- (c) when A4 is His, then A3 is not Glu, Leu, or Lys.
(canceled)
7-8. (canceled)
10-12. (canceled)
An isolated polypeptide of any one of the following structural formulas, or a pharmaceutically acceptable salt thereof:
- (SEQ ID NO:
- 61)
- Ac-Arg-cyclo[Cys-D-Leu-His-D-Phe-Arg-Trp-Cys]-NH2;
- (SEQ ID NO:
- 62)
- Ac-Arg-cyclo[Cys-D-Ile-His-D-Phe-Arg-Trp-Cys]-NH2;
- (SEQ ID NO:
- 63)
- Ac-Arg-cyclo[Cys-D-Tle-His-D-Phe-Arg-Trp-Cys]-NH2;
- or
- (SEQ ID NO:
- 10)
- Ac-Arg-cyclo[Cys-D-Val-His-D-Phe-Arg-Trp-Cys]-NH2,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.